E. Ohman J or Asset Management AB Purchases 7,090 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

E. Ohman J or Asset Management AB raised its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 14.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 57,590 shares of the biopharmaceutical company's stock after buying an additional 7,090 shares during the quarter. E. Ohman J or Asset Management AB's holdings in Gilead Sciences were worth $5,320,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in GILD. HHM Wealth Advisors LLC raised its holdings in shares of Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 154 shares in the last quarter. nVerses Capital LLC bought a new position in shares of Gilead Sciences in the third quarter worth about $25,000. Decker Retirement Planning Inc. acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at approximately $29,000. Valued Wealth Advisors LLC grew its holdings in shares of Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 161 shares during the last quarter. Finally, Crews Bank & Trust acquired a new position in Gilead Sciences during the 4th quarter worth approximately $31,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on GILD shares. Royal Bank of Canada restated a "sector perform" rating and set a $84.00 price objective on shares of Gilead Sciences in a research report on Monday. Robert W. Baird increased their price target on Gilead Sciences from $80.00 to $95.00 and gave the stock a "neutral" rating in a report on Thursday, November 7th. Barclays increased their target price on shares of Gilead Sciences from $84.00 to $95.00 and gave the stock an "equal weight" rating in a research note on Thursday, November 7th. Daiwa America raised Gilead Sciences to a "hold" rating in a research report on Monday, November 18th. Finally, JPMorgan Chase & Co. raised their price target on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an "overweight" rating in a research report on Wednesday, January 29th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $98.39.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock traded down $2.04 on Friday, reaching $96.00. The stock had a trading volume of 5,038,943 shares, compared to its average volume of 6,810,370. The business's 50 day moving average is $92.97 and its two-hundred day moving average is $86.49. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The company has a market cap of $119.64 billion, a P/E ratio of 1,066.67, a price-to-earnings-growth ratio of 1.37 and a beta of 0.18. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $100.51.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm had revenue of $7.55 billion for the quarter, compared to analysts' expectations of $7.01 billion. During the same quarter in the prior year, the firm posted $2.29 earnings per share. The business's quarterly revenue was up 7.0% on a year-over-year basis. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 4.34 EPS for the current year.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares in the company, valued at approximately $11,863,898.55. This represents a 1.89 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Merdad Parsey sold 164,211 shares of the stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total value of $15,094,275.12. Following the transaction, the insider now owns 80,801 shares in the company, valued at $7,427,227.92. This trade represents a 67.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 572,824 shares of company stock valued at $53,611,715 in the last 90 days. Corporate insiders own 0.29% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.